Clinical Trials Arena: Alphyn prepares for two global trials in atopic dermatitis by Urtė Fultinavičiūtė NEWS PROVIDED BY Alphyn Biologics July 26, 2023 Alphyn is planning to open sites in the US, Canada, Europe and Australia. Read the Clinical Trials Arena article here. CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas…
Healio: Interim results show AB-101a significantly controls atopic dermatitis skin bacteria by Gabrielle Capaldo NEWS PROVIDED BY Alphyn Biologics July 17, 2023 80% of patients achieved an itch score improvement of 4 points or more. 90% of patients achieved EASI 50 and 44% achieved EASI 75. Read the Healio article here. CONTACTS Corporate: Neal…
Dermatology Times: Alphyn Biologics Shares Positive Interim Results of Phase 2a Trial for AD With Secondary Bacterial Infection Kaitlyn Bader, Senior Editor NEWS PROVIDED BY Alphyn Biologics July 14, 2023 AB-101a is a new topical treatment being investigated for mild, moderate, and severe atopic dermatitis and its immune system component. Read the Dermatology Times article…
Healio: AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis by Gabrielle Capaldo NEWS PROVIDED BY Alphyn Biologics July 14, 2023 53.3% of pediatric patients treated with AB-101a achieved a 1-point decrease in IGA vs. 0% of those treated with vehicle. This outcome was also seen in 60% of…
Society for Pediatric Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild, Moderate, and Severe Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics July 13, 2023, 19:30 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
Dermatology Times: Topical Therapeutic Shows Significant Improvement in Mild-to-Moderate Atopic Dermatitis Heather Raglin, Editor NEWS PROVIDED BY Alphyn Biologics July 11, 2023 Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon. Read the Dermatology Times article here. CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com…
World Congress of Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics July 6, 2023, 10:00 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
European Society for Pediatric Dermatology Poster Presentation: Pediatric Data from Phase 2a Trial of AB-101a for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics May 4, 2023, 07:25 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
VIDEO: Alphyn Biologics’ atopic dermatitis candidate shows positive early results NEWS PROVIDED BY Alphyn Biologics Mar 21, 2023 In this Healio video exclusive from the American Academy of Dermatology Annual Meeting, Neal Koller, founder and CEO of Alphyn Biologics, discusses the clinical-stage company’s drug pipeline. View the video here. CONTACTS Corporate: Neal Koller…
Empowered Patient Podcast: Treating Atopic Dermatitis Using Therapeutic Drug Containing Multiple Bioactive Compounds with Neal Koller Alphyn Biologics NEWS PROVIDED BY Alphyn Biologics Feb 27, 2023 Neal Koller, CEO of Alphyn Biologics, discusses their first topical drug which treats both atopic dermatitis and atopic dermatitis with secondary infection. Listen to the podcast here. CONTACTS…